Streamline Health Posts Wider Q1 Loss Amid Revenue Growth

TL;DR

**Streamline Health is still bleeding cash, making it a risky bet despite slight revenue bumps.**

AI Summary

STREAMLINE HEALTH SOLUTIONS INC. reported a net loss of $6,064,000 for the three months ended April 30, 2025, a significant increase from the $5,655,000 net loss in the prior-year period. Revenue for the quarter was $7,092,000, up from $6,762,000 in the same period last year, representing a 4.89% increase. Diluted net loss per share was $0.01 for both periods. The company's total assets were $28,988,000 as of April 30, 2025. Key business changes include the issuance of common stock as part of the Avelead Consulting, LLC acquisition earnout liability on March 27, 2024, which also led to a $159,000 valuation adjustment. Risks include the ongoing net losses and the exclusion of anti-dilutive shares from diluted EPS calculations, indicating potential future dilution. The strategic outlook appears focused on integrating acquisitions and managing earnout liabilities, while still facing profitability challenges.

Why It Matters

STREAMLINE HEALTH SOLUTIONS INC.'s continued net losses, despite a modest revenue increase, signal ongoing challenges in achieving profitability, which could erode investor confidence and impact stock performance. For employees, sustained losses might raise concerns about job security or future growth opportunities. Customers could face uncertainty regarding the company's long-term stability and ability to invest in product development, especially in the competitive healthcare IT sector. The broader market will watch if Streamline Health can leverage its acquisitions, like Avelead, to turn around its financial performance and compete effectively against larger, more profitable rivals.

Risk Assessment

Risk Level: high — The company reported a net loss of $6,064,000 for the three months ended April 30, 2025, an increase from $5,655,000 in the prior year. This persistent and increasing net loss, coupled with a diluted net loss per share of $0.01 for both periods, indicates significant financial instability and a high risk of continued unprofitability.

Analyst Insight

Investors should exercise extreme caution and consider avoiding STREAMLINE HEALTH SOLUTIONS INC. until there is clear evidence of sustained profitability. Monitor future filings for a significant reduction in net losses and positive cash flow from operations before considering an investment.

Financial Highlights

revenue

$7,092,000

total Assets

$28,988,000

net Income

-$6,064,000

eps

-$0.01

revenue Growth

+4.89%

Key Numbers

• $7,092,000 — Revenue (for the three months ended April 30, 2025, up from $6,762,000 in the prior year)
• $6,064,000 — Net Loss (for the three months ended April 30, 2025, an increase from $5,655,000 in the prior year)
• $0.01 — Diluted Net Loss Per Share (for the three months ended April 30, 2025 and 2024)
• $28,988,000 — Total Assets (as of April 30, 2025)
• $159,000 — Valuation Adjustment (recorded on March 27, 2024, related to Avelead acquisition earnout liability)
• 218,352 — Unvested Restricted Shares (outstanding as of April 30, 2025, excluded from diluted EPS)
• 237,027 — Shares from Warrants (issuable through exercise of warrants, excluded from diluted EPS for Q1 2025)

Key Players & Entities

• STREAMLINE HEALTH SOLUTIONS INC. (company) — filer of the 10-Q
• Avelead Consulting, LLC (company) — acquired company with an earnout liability
• Wyche “Tee” Green, III (person) — Executive Chairman and Board member, managing member of 121G, LLC
• 121G, LLC (company) — entity whose securities may be beneficially owned by Wyche “Tee” Green, III
• Justin J. Ferayorni (person) — Board member and co-trustee of The Ferayorni Family Trust
• The Ferayorni Family Trust (company) — entity whose securities may be beneficially owned by Justin J. Ferayorni
• Mr. Etheridge (person) — Board member subsequent to Debt Private Placement
• Mr. Phillips (person) — Board member

FAQ

Risk Factors

• Persistent Net Losses [high — financial]: The company reported a net loss of $6,064,000 for the three months ended April 30, 2025, an increase from the $5,655,000 net loss in the prior-year period. This ongoing trend of net losses raises concerns about the company's ability to achieve profitability and sustain its operations.
• Potential Share Dilution [medium — financial]: Diluted net loss per share excludes a significant number of potentially dilutive securities, including 218,352 unvested restricted shares and 237,027 shares from warrants as of April 30, 2025. The future exercise or vesting of these instruments could substantially dilute existing shareholders' ownership.
• Acquisition Integration and Earnout Management [medium — operational]: The company is actively managing earnout liabilities from acquisitions, such as the $159,000 valuation adjustment related to Avelead Consulting, LLC on March 27, 2024. Successful integration of acquired businesses and effective management of contingent payment obligations are critical for future performance.

Industry Context

Streamline Health Solutions operates in the healthcare technology sector, specifically focusing on revenue cycle management and data analytics solutions for healthcare providers. This industry is characterized by increasing demand for efficiency and cost reduction, driven by complex billing processes and evolving regulatory landscapes. Competition is present from established players and emerging technology firms offering specialized solutions.

Regulatory Implications

The healthcare industry is subject to stringent regulations, including HIPAA for data privacy and security. Companies like Streamline Health must ensure their solutions comply with these regulations to avoid significant penalties. Changes in healthcare reimbursement policies can also impact the demand for their services.

What Investors Should Do

1. Monitor revenue growth trajectory and profitability trends.
2. Assess the impact of potential share dilution.
3. Evaluate the success of recent acquisitions and earnout management.

Key Dates

• 2024-03-27: Issuance of common stock for Avelead acquisition earnout liability — This event involved a $159,000 valuation adjustment and highlights the company's use of stock for acquisition-related payments, impacting its capital structure and potentially diluting existing shareholders.
• 2025-04-30: End of the three-month reporting period — This date marks the period for which the 10-Q financial results are reported, showing increased net loss and modest revenue growth compared to the prior year.

Glossary

Diluted Net Loss Per Share

The net loss per share after accounting for all dilutive potential common shares, such as stock options, warrants, and convertible securities. However, if these potential shares would increase the net loss per share, they are excluded. (The company excludes a significant number of potential shares from this calculation, indicating that their actual impact on EPS could be worse if they were included.)

Unvested Restricted Shares

Shares of company stock granted to employees or executives that are subject to certain conditions (like continued employment) before they become fully owned by the recipient. (As of April 30, 2025, 218,352 unvested restricted shares were outstanding and excluded from diluted EPS calculations, representing potential future dilution.)

Warrants

Financial instruments that give the holder the right, but not the obligation, to purchase a company's stock at a specified price within a certain timeframe. (237,027 shares issuable through warrants were excluded from diluted EPS for Q1 2025, indicating potential future dilution upon exercise.)

Earnout Liability

A contingent obligation to pay additional consideration to the seller of a business based on the future performance of the acquired business. (The company is managing earnout liabilities, as evidenced by the issuance of stock and a $159,000 valuation adjustment related to the Avelead acquisition.)

Year-Over-Year Comparison

For the three months ended April 30, 2025, Streamline Health Solutions Inc. reported revenue of $7,092,000, a 4.89% increase from $6,762,000 in the prior year. However, the net loss widened to $6,064,000 from $5,655,000 in the same period last year. Diluted net loss per share remained flat at $0.01 for both periods, but this figure excludes a notable number of potentially dilutive shares. Total assets stood at $28,988,000 as of April 30, 2025.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on June 16, 2025 by Wyche “Tee” Green, III regarding STREAMLINE HEALTH SOLUTIONS INC..

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR